The National Institutes of Health today awarded about $470 million from the American Rescue Plan Act to New York University Langone Health for a project to study the long-term effects of COVID-19. The RECOVER (Researching COVID to Enhance Recovery) initiative will work with more than 100 researchers to support new and existing studies of COVID-19 survivors to learn why some people have prolonged symptoms or develop new or returning symptoms after SARS-CoV-2 infection, and potential prevention and treatment strategies. The studies will enroll adult, pregnant and pediatric patients during the acute and post-acute phases of infection; evaluate tissue pathology and electronic health records; and use smartphone apps and other mobile technologies to gather data in real time. 

“Given the range of symptoms that have been reported, intensive research using all available tools is necessary to understand what happens to stall recovery from this terrible virus,” said Walter Koroshetz, M.D., director of NIH’s National Institute of Neurological Disorders and Stroke and co-chair of the initiative. “Importantly, the tissue pathology studies in RECOVER will enable in depth studies of the virus’s effects on all body systems.”
 

Related News Articles

Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…